ESR1 and vulva cancer: The estrogen receptor modulator ospemifene was found to be helpful for the prevention of vaginal and vulvar cancer and atrophy in women with dyspareunia in a study of 605 postmenopausal women using oral ospemifene 60 mg/day for 12 weeks [140].